Skip to main content
OpenTrials
Completed

NCT Number: NCT02925143

Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning

To assess the impact of an e-learning course in neuromuscular monitoring on the frequency of application of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia and secondarily on the incidence of residual neuromuscular blockade after anesthesia.

We will collect data prospectively from 6 Danish anaesthesia departments from the time of intervention, using data from the Anaesthesia Information Management System (AIMS). Baseline data is obtained from another study based on the same data extraction procedure (NCT02914119).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromuscular Blockade

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Herlev Hospital

Herlev, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion Departments We will include the 6 largest anaesthesia departments in the Zealand Region of Denmark.

Anaesthetists We will include the following anaesthesia personnel as anaesthetists: nurse anaesthetists in training, nurse anaesthetists, first year residents in anaesthesiology, residents in the last 4 years of training in anaesthesiology, and specialist consultants in anaesthesia.

Patients We will include and collect data from all patients undergoing general anaesthesia with neuromuscular blockade in each data collection period. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses with a case for every general anaesthetic received.

Exclusion criteria

We will exclude personnel without clinical functions, i.e. administrative personnel.

Treatment and study plan

E-learning course in neuromuscular monitoring

Other

An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.

Primary outcomes

  1. Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no)

    Time frame: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

    Number of Participants Who Received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.

  2. Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing NMBA (Yes/no)

    Time frame: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

    Number of Participants Who Received a Non-depolarizing Neuromuscular Blocking Agent (NMBA) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.

Secondary outcomes

  1. Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA

    Time frame: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours]

    The Train-of-four (TOF) ratio is the ratio of the fourth to the first muscle response after 4 stimuli at the ulnar nerve at the wrist at 2 Hz. The response is measured using acceleromyography. If the last measurement is performed before return of any muscle function, the ration can not be given.

  2. Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)

    Time frame: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours

    If the total dose of sugammadex in the anaesthesia information management system is > 0, the outcome is "yes".

  3. Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)

    Time frame: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours

    If the total dose of neostigmine in the anaesthesia information management system is > 0, the outcome is "yes".

  4. Administration of More Than One Reversal Agent in Cases Receiving a Non-depolarizing NMBA (Yes/no)

    Time frame: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours

    If the total dose of neostigmine is bigger than (>) the first dose administered, the outcome is "yes".

  5. Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA

    Time frame: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes

Sponsors and collaborators

Lead sponsor

Herlev Hospital

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning - a Multicenter Interrupted Time Series Study (INVERT Study)

Acronym: INVERT

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Oct 5, 2016
Registry last updated
May 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.